4PKB Stock Overview
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$3.66 |
| 52 Week Low | US$1.05 |
| Beta | 0.68 |
| 1 Month Change | -9.66% |
| 3 Month Change | 63.75% |
| 1 Year Change | 55.95% |
| 3 Year Change | -72.42% |
| 5 Year Change | n/a |
| Change since IPO | -78.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4PKB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.7% | -1.8% | 1.1% |
| 1Y | 56.0% | -24.9% | 6.5% |
Return vs Industry: 4PKB exceeded the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 4PKB exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 4PKB volatility | |
|---|---|
| 4PKB Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4PKB's share price has been volatile over the past 3 months.
Volatility Over Time: 4PKB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| 4PKB fundamental statistics | |
|---|---|
| Market cap | €74.34m |
| Earnings (TTM) | -€38.79m |
| Revenue (TTM) | €6.26m |
11.2x
P/S Ratio-1.8x
P/E RatioIs 4PKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4PKB income statement (TTM) | |
|---|---|
| Revenue | US$6.77m |
| Cost of Revenue | US$3.48m |
| Gross Profit | US$3.29m |
| Other Expenses | US$45.26m |
| Earnings | -US$41.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 48.56% |
| Net Profit Margin | -620.09% |
| Debt/Equity Ratio | 10.3% |
How did 4PKB perform over the long term?
See historical performance and comparison